In 2017, a clinical researcher in the United Kingdom faced a daunting task: developing a national database for myelofibrosis, a rare and complex blood cancer. Traditional database platforms had proven insufficient, lacking the necessary functionality for efficient data representation and analysis. The challenge was significant, and progress had been slow, taking four long years without substantial results.
Searching for a more powerful solution, the researcher turned to Ledidi Core, an all-in-one solution designed to streamline data management and analysis. Ledidi Core provided the critical capabilities needed for this ambitious project, allowing multiple users to collaborate seamlessly on a shared dataset while offering robust data visualisation and statistical analysis tools, all within a single, user-friendly application.
"As a clinical researcher, I was very familiar with creating databases on different platforms, but these databases had very limited functionality in terms of representing data graphically and analytically. Whereas the Ledidi solution allows multiple users to work on one platform collecting a common dataset that can be analysed within the platform itself.
In 2017, I was tasked to develop a national database for a rare blood cancer, known as myelofibrosis. I realised that this was going to be a challenge, and so, when we moved on to the Ledidi platform, the functionality that we could produce by the click of a button, was more than we had managed to create in four years on the previous platform.
The versatility, the elegance with which the platform captures the data, which can then be analysed all in one application, was absolutely unique, and I have not seen anything like that on a research platform before." -- Dr. Nauman Butt, The Clatterbridge Cancer Centre, NHS Foundation Trust.
Ledidi Core significantly expedited the development of the myelofibrosis databaset. This success showcases Ledidi Core's transformative impact, saving time and enhancing research while accelerating medical discoveries.